Illumina and Broad Institute Announce Strategic Collaboration to Advance Single-Cell Sequencing Technologies

● Supported by a core genomics portfolio, the company is well-positioned to achieve high single-digit revenue growth over the next three years.

● Through innovation, develop transformative applications using multi-omics technologies;

●Illumina provides customers with higher-quality services, helping them enhance the overall experience of end-to-end workflows and reduce costs.

●Double-Digit Growth in Non-GAAP Diluted Earnings Per Share from 2025-2027；

● Illumina and the Broad Institute of MIT and Harvard Announce New Research Partnership to Advance Single-Cell Sequencing Technology

Illumina CEO Jacob Thaysen said, "Illumina has laid the foundation for the genomics industry, and we will continue to lead innovation across the entire sequencing workflow to support our customers' next phase of success. In the next three years, we will introduce exciting innovations to the market that will redefine genomes and drive significant, deeper biological research through multi-omics technologies."

Illumina also announced a new research partnership with the Broad Institute to advance single-cell sequencing using Illumina's Fluent technology and accelerate the adoption of high-throughput single-cell experiments. As part of the collaboration, Illumina and the Broad Institute will work together to develop and validate new kits to facilitate large-scale Perturb-seq CRISPR screens.

Niall Lennon, Senior Director of the Genomics Platform at the Broad Institute, stated: "Expanding our research collaboration with Illumina to include Fluent technology will support the Broad Institute’s goal of achieving billion-cell experiments. Single-cell sequencing has revolutionized biomedical research in ways that were unimaginable 15 years ago. Today, it is one of the most exciting fields in biology."

Illumina is building new, scalable growth businesses to complement and accelerate its high-intensity,High-throughput SequencingFranchise. The company is implementing a series of innovations to meet the evolving needs of customers.These innovations will help them:

● Reshape the Genome: Revolutionize workflows through innovative sample preparation and integrated software, leading to broader applications of Whole Genome Sequencing (WGS).

● Initiate deeper biological research: Through interpretation andVisualization Tool, enabling a complete multi-omics workflow and delivering deeper biological insights.

● By providing a complete workflow solution from sample to biological discovery, including first-class software and informatics capabilities, enabling next-generation sequencing (NGS) are easy to handle in the laboratory, paving the way for in-depth and comprehensive analysis.

● Transforming Data into Discoveries: Providing software/AI platforms to integrate and analyze large data cohorts, decrypting variants of uncertain significance.

Illumina expects that by 2027, its strategy will accelerate the company's revenue growth to a high single-digit percentage. The company aims to drive double-digit growth in non-GAAP diluted earnings per share (EPS) from 2025 to 2027 by accelerating revenue growth, improving operational efficiency, and adopting a systematic and disciplined approach to allocating significant free cash flow.

"We have the right strategy to restore growth and enhance profitability. In a challengingMacroeconomic Environment"Currently, we are executing this strategy and strengthening Illumina's relationships with our customers. Looking ahead, we aim to see accelerated revenue growth over the next three years, along with differentiated profit expansion," said Ankur Dhingra, Chief Financial Officer of Illumina.

Source of information: https://www.prnewswire.com/

---The End---